Development of MicroRNA Therapeutics for Hepatocellular Carcinoma

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2016 Feb 3

PMID 26835673

Citations 9

Authors

Rajagopal N Aravalli

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. Treatment options for HCC are very limited, as it is often diagnosed at a late stage. Recent studies have demonstrated that microRNAs (miRNAs), a class of non-coding RNAs, are aberrantly expressed in HCC. Some of these were shown to be functionally involved in carcinogenesis and tumor progression, suggesting that miRNAs can serve as novel molecular targets for HCC therapy. Several promising studies have recently demonstrated the therapeutic potential of miRNAs in animal models and in reducing the viral load in hepatitis C patients. In this review, these advances and strategies for modulating miRNAs for in vivo therapeutic delivery and replacement therapy are discussed.

Citing Articles

MicroRNA and liver cancer.

Onishi M, Ochiya T, Tanaka Y Cancer Drug Resist. 2022; 3(3):385-400.

PMID: 35582451 PMC: 8992476. DOI: 10.20517/cdr.2019.110.

Modulating microRNAs in cancer: Next-generation therapies.

Arghiani N, Shah K Cancer Biol Med. 2021; .

PMID: 34846108 PMC: 8958885. DOI: 10.20892/j.issn.2095-3941.2021.0294.

MicroRNA-490-3p suppresses hepatocellular carcinoma cell proliferation and migration by targeting the aurora kinase A gene ().

Zhang H, Bao J, Zhao S, Huo Z, Li B Arch Med Sci. 2020; 16(2):395-406.

PMID: 32190151 PMC: 7069437. DOI: 10.5114/aoms.2019.91351.

Circular RNA expression and circPTPRM promotes proliferation and migration in hepatocellular carcinoma.

Luo Z, Mao X, Cui W Med Oncol. 2019; 36(10):86.

PMID: 31494761 DOI: 10.1007/s12032-019-1311-z.

Adipokines Regulate the Expression of Tumor-Relevant MicroRNAs.

Jasinski-Bergner S, Kielstein H Obes Facts. 2019; 12(2):211-225.

PMID: 30999294 PMC: 6547259. DOI: 10.1159/000496625.

References

Lu Y, Xiao J, Lin H, Bai Y, Luo X, Wang Z . A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res. 2009; 37(3):e24. PMC: 2647303. DOI: 10.1093/nar/gkn1053. View

Li D, Liu X, Lin L, Hou J, Li N, Wang C . MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 2011; 286(42):36677-85. PMC: 3196113. DOI: 10.1074/jbc.M111.270561. View

Ibrahim A, Weirauch U, Thomas M, Grunweller A, Hartmann R, Aigner A . MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011; 71(15):5214-24. DOI: 10.1158/0008-5472.CAN-10-4645. View

Blum H . Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2006; 11(47):7391-400. PMC: 4725160. DOI: 10.3748/wjg.v11.i47.7391. View

Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C . Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007; 67(13):6092-9. DOI: 10.1158/0008-5472.CAN-06-4607. View

Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant B, Slagle B . Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol. 2008; 173(3):856-64. PMC: 2527078. DOI: 10.2353/ajpath.2008.080096. View

Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K . Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010; 17(6):398-408. DOI: 10.1038/cgt.2009.88. View

Callegari E, Elamin B, Giannone F, Milazzo M, Altavilla G, Fornari F . Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology. 2012; 56(3):1025-33. DOI: 10.1002/hep.25747. View

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

10.

Yuan K, Lian Z, Sun B, Clayton M, Ng I, Feitelson M . Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One. 2012; 7(4):e35331. PMC: 3322146. DOI: 10.1371/journal.pone.0035331. View

11.

Van Kouwenhove M, Kedde M, Agami R . MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer. 2011; 11(9):644-56. DOI: 10.1038/nrc3107. View

12.

Takei Y, Takigahira M, Mihara K, Tarumi Y, Yanagihara K . The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. Cancer Res. 2010; 71(4):1442-53. DOI: 10.1158/0008-5472.CAN-10-2530. View

13.

Wiggins J, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D . Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010; 70(14):5923-30. PMC: 2913706. DOI: 10.1158/0008-5472.CAN-10-0655. View

14.

Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R . Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009; 49(4):1098-112. DOI: 10.1002/hep.22749. View

15.

Braconi C, Henry J, Kogure T, Schmittgen T, Patel T . The role of microRNAs in human liver cancers. Semin Oncol. 2011; 38(6):752-63. PMC: 3928803. DOI: 10.1053/j.seminoncol.2011.08.001. View

16.

Tomokuni A, Eguchi H, Tomimaru Y, Wada H, Kawamoto K, Kobayashi S . miR-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2011; 414(4):675-80. DOI: 10.1016/j.bbrc.2011.09.124. View

17.

Chen Y, Zhu X, Zhang X, Liu B, Huang L . Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010; 18(9):1650-6. PMC: 2956922. DOI: 10.1038/mt.2010.136. View

18.

Lindow M, Kauppinen S . Discovering the first microRNA-targeted drug. J Cell Biol. 2012; 199(3):407-12. PMC: 3483128. DOI: 10.1083/jcb.201208082. View

19.

Ebert M, Neilson J, Sharp P . MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007; 4(9):721-6. PMC: 3857099. DOI: 10.1038/nmeth1079. View

20.

Datta J, Kutay H, Nasser M, Nuovo G, Wang B, Majumder S . Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008; 68(13):5049-58. PMC: 2562630. DOI: 10.1158/0008-5472.CAN-07-6655. View